INTRODUCTION {#s1}
============

Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide \[[@R1]\]. It consists of the luminal A, luminal B (HER2-negative), luminal B (HER2-positive), HER2-positive (non-luminal), and triple-negative (ductal) subtypes. Approximately 15% of invasive breast cancers are triple-negative breast cancers (TNBC) that lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expressions and usually exhibit a high pathological grade and more aggressive clinical behavior. Currently, chemotherapy is the only systemic treatment modality for TNBC patients.

The spindle assembly checkpoint (SAC) is a signaling cascade that prevents chromosome missegregation by arresting mitosis until all chromosomes are properly attached to the mitotic spindle \[[@R2]\]. As the core SAC kinase, TTK kinase is a dual-specificity kinase able to phosphorylate serine/threonine and tyrosine residues \[[@R3]\], and critical for the recruitment of SAC proteins to unattached kinetochores, mitotic checkpoint complex (MCC) formation, and mitotic arrest \[[@R4]\]. Thus, the inhibition of TTK activity causes cells to prematurely exit mitosis with unattached chromosomes, resulting in severe chromosome missegregation, aneuploidy, and eventually cell death \[[@R5]--[@R8]\]. The increased expression of mitotic checkpoint genes contributes to chromosomal instability in cancer cells \[[@R9]--[@R12]\]. Elevated TTK mRNA levels are found in several human cancers, including thyroid carcinoma, breast cancer, lung cancer, pancreatic cancer, prostate cancer, and melanoma, as well as glioblastoma and hepatocellular carcinoma---where it is associated with poor prognosis \[[@R9], [@R11], [@R13]-[@R18]\].

Previous studies show that TTK is overexpressed in breast cancer tissue and cells, particularly in the HER2-positive and TNBC subtypes \[[@R9], [@R10], [@R19], [@R20]\]. Whether it is also a prognostic factor in TNBC remains disputed. In the current study, we retrospectively analyzed TTK expression in 169 TNBC samples and investigated the correlation between TTK expression and TNBC prognosis.

RESULTS {#s2}
=======

Clinicopathological characteristics and survival data of the cohort {#s2_1}
-------------------------------------------------------------------

The present study enrolled 169 consecutive TNBC cases (Table [1](#T1){ref-type="table"}). The median age of patients at surgery was 51 years (range, 16--81 years). Most cases were immediate- to high-grade invasive breast ductal carcinoma (162/169, 95.5%), and 91.7% (155/169) of patients received a modified radical mastectomy. Of cases with available adjuvant treatment information, 99.3% (134/135) received chemotherapy (one ceased treatment because of an allergic reaction) and 34.3% (48/140) received radiation. Five cases lost follow-up. The median overall follow-up period was 1864 days (range, 1104--2373 days), and the five-year DFS and OS rates were 76.2% and 90.6%, respectively.

###### Baseline clinicopathological characteristics and treatments of the cohort

  Characteristics (n=169)                    Values
  ------------------------------------------ -------------------
  **Age at diagnosis:**                      
   Median, range (years)                     51 (26\~81)
   \<40                                      30 (17.8%)
   40\~59                                    103 (60.9%)
   ≥60                                       36 (21.3%)
  **surgery**                                
   MRM                                       155 (91.7%)
   BCS                                       14 (8.3%)
  **Histology subtype**                      
   IDC                                       162 (95.9%)
   others                                    7 (4.1%)
  **Grade**                                  
   Low                                       1 (0.6%)
   Intermediate                              43 (25.4%)
   High                                      125 (74%)
  **Lymphovascular invasion**                
   No                                        156 (92.3%)
   Yes                                       13 (7.7%)
  **Tumor size, cm**                         
   ≤2                                        82 (48.5%)
   2\~5                                      80 (47.3%)
   \>5                                       7 (4.1%)
  **Number of positive lymph nodes**         
   0                                         89 (52.7%)
   1\~3                                      36 (21.3%)
   4\~9                                      21 (12.4%)
   ≥10 or 3^rd^ stop metastasis              23 (13.6%)
  **Pathologic stage**                       
   I                                         49 (29.0%)
   II                                        73 (43.2%)
   III                                       47 (27.8%)
  **Ki67**                                   
   \<20%                                     16 (9.5%)
   ≥20%                                      153 (90.5%)
  **P53 status**                             
   Negative                                  75 (44.4%)
   Positive                                  94 (55.6%)
  **Molecular subtype**                      
   Basal-like TNBC                           97 (57.4%)
   Non basal-like TNBC                       38 (22.5%)
   NA                                        34 (20.1%)
  **Chemotherapy**                           
   None[\*](#tfn_001){ref-type="table-fn"}   1 (0.6%)
   A-based                                   34 (20.1%)
   T-based                                   21 (12.4%)
   AT-based                                  67 (39.6%)
   Others                                    13 (7.7%)
   NA                                        34 (20.1%)
  **Radiation**                              
   No                                        92 (54.4%)
   Yes                                       48 (28.4%)
   NA                                        29 (17.2%)
  **Follow-up**                              
   Median, range (days)                      1864 (1104\~2373)
   5-y disease free rate (%)                 76.2
   5-y survival rate (%)                     90.6

One ceased chemotherapy because of an allergic reaction

Abbreviations: MRM modified radical mastectomy, BCS breast-conserving surgery, IDC invasive ductal carcinoma, NA not available, A anthrocycline, T taxanes.

TTK expression and cutpoint determination {#s2_2}
-----------------------------------------

TTK expression was analyzed in 169 patients. Most samples (168/169, 99.4%) displayed cytoplasm and membrane staining, of which 10 cases (5.9%) had concomitant nuclear expression (Table [2](#T2){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). Both "H-score. Cytoplasm & membrane" and "H-score. Whole cell" methods yielded a cutoff value of 55 with nearly identical *p* values (*p* \< 0.001, Figure [2](#F2){ref-type="fig"}); however, the area under the curve (AUC) was slightly higher in the whole cell staining analysis, thus this scoring method was selected and the discriminating threshold set at 55.

###### TTK expression results

  -----------------------------------------------------------------------------------------
                                           Positive cells rate (%)\   Number of cases (%)
                                           Median (range)             
  ---------------------------------------- -------------------------- ---------------------
  **Cytoplasm & membrane only staining**                              

   Negative                                0                          1 (0.6%)

   Positive                                90 (5\~220)                168 (99.4%)

     1+                                    40 (5\~90)                 165 (97.6%)

     2+                                    20 (5\~80)                 123 (72.8%)

     3+                                    7.5 (5\~40)                32 (18.9%)

  **Nucleus staining**                                                

   Negative                                0                          159 (94.1%)

   Positive                                40 (5\~160)                10 (5.9%)

     1+                                    25 (5\~40)                 6 (3.6%)

     2+                                    80 (30\~80)                4 (2.4%)

     3+                                    10                         1 (0.6%)

  **Whole cell staining**                                             

   Negative                                0                          1 (0.6%)

   Positive                                90 (5\~340)                168 (99.4%)
  -----------------------------------------------------------------------------------------

![Representative immunohistochemical results of TTK positive tumor cells\
**a.**, **b.**, **c.** showing TTK cytoplasm and membrane positivity with 3+, 2+ and 1+ intensity respectively. **d.**, **e.**, **f.** showing nucleus positivity with 3+, 2+ and 1+ intensity.](oncotarget-07-81815-g001){#F1}

![Cutoff values of "H-score. Cytoplasm & membrane" and "H-score. Whole cell"\
ROC curves showed that the cutpoint of the two methods were both 55. The "H-score. Whole cell" assessment method had a little higher AUC (0.722 (0.613\~0.816)) than the former method (0.715 (0.621\~0.823)).](oncotarget-07-81815-g002){#F2}

Correlation between TTK and clinicopathological factors {#s2_3}
-------------------------------------------------------

The association between clinicopathological characteristics and TTK expression are summarized in Table [3](#T3){ref-type="table"}. No significant association was found between TTK status and age, histology subtype, grade, lymphovascular invasion (LVI), tumor size, number of positive lymph nodes, pathologic stage, Ki67 index, and p53 status; however, TTK overexpression was significantly higher in the basal-like TNBC subgroup.

###### Correlations between TTK expression and clinicopathologic characteristics

  characteristics                      TTK (n=166)   X^2^          *p*         
  ------------------------------------ ------------- ------------- ----------- -----------
  **Age at diagnosis: 51 (26\~81)**                                **2.415**   **0.299**
   \<40                                9 (5.3%)      21 (12.4%)                
   40\~59                              22 (13.0%)    81 (47.9%)                
   ≥60                                 12 (7.1%)     24 (14.2%)                
  **Histology subtype**                                            **1.289**   **0.256**
   IDC                                 43 (25.4%)    119 (70.4%)               
   others                              0 (0%)        7 (4.1%)                  
  **Grade**                                                        **0.006**   **0.937**
   Low/Intermediate                    11 (6.5%)     33 (19.5%)                
   High                                32 (18.9%)    93 (55.0%)                
  **Lymphovascular invasion**                                      **2.111**   **0.146**
   No                                  37 (21.9%)    119 (70.4%)               
   Yes                                 6 (3.6%)      7 (4.1%)                  
  **Tumor size (cm)**                                              **2.841**   **0.242**
   ≤2                                  17 (10.1%)    65 (38.5%)                
   2\~5                                25 (14.8%)    55 (32.5%)                
   \>5                                 1 (0.6%)      6 (3.6%)                  
  **Number of positive lymph nodes**                               **3.761**   **0.288**
   0                                   18 (10.8%)    71 (42.8%)                
   1\~3                                10 (6.0%)     26 (15.7%)                
   4\~9                                6 (3.0%)      15 (9.0%)                 
   ≥10 or 3^rd^ stop metastasis        9 (4.8%)      14 (7.8%)                 
  **Pathologic stage**                                             **2.344**   **0.310**
   I                                   9 (5.3%)      40 (23.7%)                
   II                                  19 (11.2%)    54 (32.0%)                
   III                                 15 (8.9%)     32 (18.9%)                
  **Ki67 index**                                                   **0.743**   **0.389**
   \<20%                               6 (3.6%)      10 (6.0%)                 
   ≥20%                                37 (21.1%)    116 (69.3%)               
  **P53 status**                                                   **0.001**   **0.977**
   Negative                            19 (11.2%)    56 (33.1%)                
   Positive                            24 (14.2%)    70 (41.4%)                
  **Molecular subtype**                                            **3.870**   **0.049**
   Basal-like TNBC                     22 (13.0%)    75 (44.4%)                
   Non basal-like TNBC                 15 (8.8%)     23 (13.6%)                
   NA                                  6 (3.6%)      28 (16.6%)                

Abbreviations: IDC invasive ductal carcinoma, A Anthracyclin, T Taxanes, NA Not available.

Survival analysis {#s2_4}
-----------------

Clinical follow-up data were available for 164 out of 169 patients. Univariate survival analysis revealed that LVI, increased tumor size, positive lymph nodes, advanced stage, specific chemotherapy regimen (Anthracycline+Taxanes (AT)-based regimen), and lower TTK expression were associated with shorter DFS (Table [4](#T4){ref-type="table"}). All of these factors excepting increased tumor size, as well as radiation therapy, were also associated with a reduced OS (Table [4](#T4){ref-type="table"}). The Kaplan-Meier curves for DFS and OS against TTK expression are shown in Figure [3](#F3){ref-type="fig"}. Conversely, age, surgery type, histology subtype, grade, p53 status, Ki67 index, and molecular subtype had no impact on survival in our study.

###### Univariate analyses of survival against various characteristics

  ---------------------------------------------------------------------------------------------------------------------
  Variables                                  No.Pat\   DFS   OS                                           
                                             (n=164)                                                      
  ------------------------------------------ --------- ----- ------------ ------------- ---- ------------ -------------
  **Age**                                                    **4.316**    **0.116**          **2.232**    **0.328**

   \<40                                      30        20                               3                 

   40\~59                                    100       17                               7                 

   ≥60                                       34        10                               5                 

  **Surgery**                                                **1.970**    **0.160**          **0.102**    **0.749**

   MRM                                       150       36                               14                

   BCS                                       14        1                                1                 

  **Histology**                                              **0.017**    **0.895**          **0.815**    **0.367**

   IDC                                       159       36                               14                

   others                                    5         1                                1                 

  **Grade**                                                  **0.402**    **0.526**          **0.244**    **0.621**

   Low/Intermediate                          42        11                               3                 

   High                                      122       26                               12                

  **LVI**                                                    **22.276**   **\<0.001**        **3.864**    **0.049**

   No                                        151       29                               12                

   yes                                       13        8                                3                 

  **P53**                                                    **0.289**    **0.591**          **0.022**    **0.883**

   Neg                                       73        15                               7                 

   Pos                                       91        22                               8                 

  **Ki67 index**                                             **1.226**    **0.268**          **2.963**    **0.085**

   \<20%                                     14        5                                3                 

   ≥20%                                      150       32                               12                

  **Tumor size**                                             **14.300**   **0.001**          **1.858**    **0.395**

   ≤2cm                                      80        11                               5                 

   2-5cm                                     78        22                               9                 

   \>5cm                                     6         4                                1                 

  **Number of positive lymph nodes**                         **32.757**   **\<0.001**        **23.720**   **\<0.001**

   0                                         89        11                               4                 

   1\~3                                      35        9                                2                 

   4\~9                                      20        5                                2                 

   ≥10 or 3^rd^ stop metastasis              20        12                               7                 

  **Stage**                                                  **18.048**   **\<0.001**        **11.361**   **0.003**

   I                                         49        4                                2                 

   II                                        73        15                               4                 

   III                                       42        18                               9                 

  **Molecular subtype**                                      **0.206**    **0.650**          **0.295**    **0.587**

   Basal-like TNBC                           96        22                               9                 

   Non basal-like TNBC                       37        9                                2                 

   NA                                        31        6                                4                 

  **Chemotherapy**                                           **10.014**   **0.018**          **11.365**   **0.010**

   None[\*](#tfn_002){ref-type="table-fn"}   1         0                                0                 

   A-based                                   34        4                                0                 

   T-based                                   21        3                                2                 

   AT-based                                  67        20                               6                 

   Others                                    12        6                                4                 

   NA                                        29        4                                3                 

  **Radiation**                                              **1.299**    **0.254**          3.848        **0.050**

   No                                        91        20                               6                 

   Yes                                       48        14                               8                 

   NA                                        35        3                                1                 

  **TTK expression**                                         **29.438**   **\<0.001**        **6.653**    **0.010**

   \<55                                      43        22                               7                 

   ≥55                                       121       15                               7                 
  ---------------------------------------------------------------------------------------------------------------------

One ceased chemotherapy because of an allergic reaction.

Abbreviations: MRM modified radical mastectomy, BCS breast-conserving surgery, IDC invasive ductal carcinoma, NA not available, A anthrocycline, T taxanes.

![Kaplan-Meier curves for DFS and overall survival OS according to TTK expression\
**a.** TTK^high^ patients had a longer DFS than TTK^low^ patients (*p*\<0.001). **b.** TTK^high^ patients had a longer OS than TTK^low^ patients (*p*=0.024).](oncotarget-07-81815-g003){#F3}

Cox regression multivariate analysis of DFS and OS revealed that TTK expression was an independent predictor for DFS (*p* \< 0.001), but not for OS, whereas the number of positive lymph nodes was an independent predictor for both DFS (*p* \< 0.001) and OS (*p* = 0.005) (Table [5](#T5){ref-type="table"}). Cox regression analysis results for other clinical variables are shown in [Supplemental Table S1--S3](#SD1){ref-type="supplementary-material"}.

###### Multivariate analysis of survival against various characteristics

                                                                          DFS     OS                                                   
  ----------------------------------------------------------------------- ------- --------------- ----------- -------- --------------- -----------
  **Age**                                                                                         **0.268**                            **0.331**
   \<40                                                                   1                                   1                        
   40\~59                                                                 0.532   0.228\~1.240                0.627    0.134\~2.929    
   ≥60                                                                    0.862   0.321\~2.310                1.715    0.341\~8.617    
  **surgery**                                                                                     **0.080**                            **0.861**
   MRM                                                                    1                                   1                        
   BCS                                                                    0.157   0.020\~1.243                1.223    0.128\~11.640   
  **Histology subtype**                                                                           **0.626**                            **0.415**
   IDC                                                                    1                                   1                        
   Others                                                                 1.691   0.205\~13.946               2.540    0.270\~23.874   **0.186**
  **Grade**                                                                                       **0.601**                            
   Low/Intermediate                                                       1                                   1                        
   High                                                                   0.815   0.379\~1.753                2.632    0.627\~11.041   
  **P53**                                                                                         **0.857**                            **0.392**
   Negative                                                               1                                   1                        
   Positive                                                               1.067   0.526\~2.164                0.597    0.183\~1.947    
  **Ki67**                                                                                        **0.662**                            **0.223**
   \<20%                                                                  1                                   1                        
   ≥20%                                                                   1.256   0.453\~3.483                0.391    0.086\~1.769    
  **Number of positive lymph nodes[\*](#tfn_003){ref-type="table-fn"}**                           **0.000**                            **0.002**
   0                                                                      1                                   1                        
   1\~3                                                                   2.256   0.915\~5.561                1.244    0.216\~7.167    
   4\~9                                                                   1.661   0.569\~4.851                1.592    0.273\~9.276    
   ≥10 or 3^rd^ stop metastasis                                           7.195   2.965\~17.459               10.690   2.814\~40.611   
  **TTK expression**                                                                              **0.000**                            **0.111**
   \<55                                                                   1                                   1                        
   ≥55                                                                    0.197   0.098\~0.398                0.394    0.125\~1.240    

Because of multicollinearity between lymphovascular invasion, tumor size, number of positive lymph nodes, and pathological stage, only number of positive lymph nodes entered Cox regression model in this table.

Abbreviations: MRM modified radical mastectomy, BCS breast-conserving surgery, IDC invasive ductal carcinoma.

Further subgroup analysis by log-rank testing showed that TTK expression associated with DFS in both basal-like (*p* = 0.001) and non-basal-like (*p* = 0.001) TNBC cases (Figure [4](#F4){ref-type="fig"}).

![Kaplan-Meier curves for DFS according to TTK expression among TNBC subgroup corhorts\
**a.** TTK^high^ patients had a longer DFS than TTK^low^ patients among basal-like TNBC cohort (*p*=0.001). **b.** TTK^high^ patients had a longer DFS than TTK^low^ patients among non basal-like TNBC cohort (*p*=0.001).](oncotarget-07-81815-g004){#F4}

DISCUSSION {#s3}
==========

In the present study, it was found that TTK expression was associated with the TNBC molecular subtype and correlated with a better prognosis. Cox regression multivariate analysis confirmed TTK expression as an independent favorable prognostic indicator for TNBC. Consistent with our results, Maire et al \[[@R20]\] reported that low TTK mRNA expression in TNBC is significantly associated with a poorer overall survival, an increased risk of metastasis, and shorter DFS. However, AI-Ejeh et al \[[@R19]\] found that TTK protein levels were elevated specifically in highly aggressive tumors, leading to poor survival of less than 2 years. Both of the two studies had small sample sizes (39 and 69, respectively), and used different methods (RNA microarray analysis and IHC analysis) to determine expression. In addition, the latter study only used staining intensity to evaluate TTK protein expression, which might be far from a sufficient semi-quantitative assessment. Here, TTK protein expression was analyzed semi-quantitatively using the H-scoring system, which accounts for both staining intensity and the percentage of positive cells. A discriminating threshold for TTK expression was then determined with ROC curve analysis. This is the first study to evaluate the impact of TTK protein expression on the survival of a consecutive TNBC cohort with the largest sample size.

TTK has universally conserved functions at kinetochores to monitor the correct bipolar attachment and tension of all chromosomes to the mitotic spindle. Loss of TTK function causes chromosomal missegregation and induces cells apoptosis, while high level of TTK enable cells with higher aneuploidy to survive \[[@R9], [@R12], [@R16]\]. However, an auto-regulatory negative feedback loop between TTK and B-Raf^WT^/ERK signaling was found in melanoma cells \[[@R21]\]. Deregulation of B-Raf/ERK signaling pathway is frequently observed and plays a central role in the carcinogenesis and maintenance of several cancers \[[@R22]\]. The negative feedback loop might exist in TNBC cells and low level of TTK activates the B-Raf/ERK signaling, which contributes to the invasiveness of cancer cells and poor survival of patients. Therefore, TTK plays a special and complicated role in breast cancer and should be regarded as an important regulator factor.

The use of TTK expression as a positive prognostic indicator may help in personalized prognosis evaluation and treatment. Apart from the traditional prognostic indicators-ER, PR and HER2, assessment of the TTK expression provides additional prognostic information. For example, in patients with early breast cancer of hormone receptor positive and HER2 negative, a high level of TTK expression predicts a good survival and may spare adjuvant chemotherapy safely. However, a low level of TTK expression may hint the need of cytotoxic agents. The data also identified a low TTK-expression TNBC subset with significantly worse prognosis in both basal-like and non-basal-like tumors. The molecular subgroup which was ER^--^/PR^--^/HER2^--^/TTK^low^ presented a quadrate-negative phenotype and was defined as quadrate-negative breast cancer (QNBC) in the current study. In other words, the four-biomarker panel can identify some TNBC cases with dismal prognosis which might require more intense treatment than others.

Numerous studies suggest that TTK may be a promising drug target for anticancer therapy, and several small-molecule inhibitors targeting this kinase are currently under development \[[@R5]--[@R8], [@R23]--[@R25]\] or have entered the clinic (BAY 1161909, NCT02138812; BAY 1217389, NCT02366949) \[[@R26]\]. However, the patient groups that would benefit from TTK-targeted therapy remain unclear. Moreover, because TTK is expressed in all proliferating human cells \[[@R27]\], these inhibitors should be used cautiously to avoid severe adverse effects. TTK-567(SYRNEIAYL) epitope peptide was also used to elicit cytotoxic T lymphocytes to establish cancer vaccines in lung, esophageal and advanced biliary tract cancers \[[@R28], [@R29]\].

This study has several limitations, primarily its retrospective nature and single-institution sample. The lack of a standard method to assess TTK expression is also a disadvantage. In addition, multicollinearity existed between lymph-vascular invasion, tumor size, number of positive lymph nodes, and pathological stage in the clinicopathological data, but these characteristics were considered separately in the Cox regression model. The Cox regression analysis showed TTK expression not an independent impact factor for OS. It might contribute to the small number of deaths and relative short follow-up period. For these reasons, a multi-institution prospective study with all molecular subtypes will be required to verify the prognostic role of TTK and to further assess the clinical significance of QNBC group.

In conclusion, while these findings should be confirmed with a larger patient population, our results suggest that TTK expression is a favorable independent prognostic biomarker for TNBC survival.

MATERIALS AND METHODS {#s4}
=====================

Patients and tumor specimens {#s4_1}
----------------------------

The study population included patients with unilateral TNBC who received curative surgery and adjuvant treatment according to guidelines at the Department of Breast Surgery of Peking Union Medical College Hospital (PUMCH) between January 2010 and June 2013. Cases with insufficient paraffin-embedded tumor tissue or those treated with neoadjuvant therapy were excluded from the study, resulting in a total of 169 consecutive enrolled patients (Figure [5](#F5){ref-type="fig"}). The follow-up period lasted from the date of surgery until June 2016. The primary endpoint was Disease-free survival (DFS) and secondary endpoint was overall survival (OS). DFS and OS intervals were defined as the time from surgery to the date of breast cancer-related relapse or death, respectively. Relapsed disease and metastasis were verified by diagnostic imaging and pathology during follow-up. This study was approved by the Ethics Committee of PUMCH and informed consent was obtained from each patient.

![Flow diagram of the study\
Total 197 consecutive TNBC cases were reviewed and 169 were included in this study. After clinicopathological and follow-up data collecting and immunohistochemistry experiment, associations between TTK expression with clinicopathological factors and survival were analyzed.](oncotarget-07-81815-g005){#F5}

Immunohistochemistry staining and analysis {#s4_2}
------------------------------------------

All tissues were fixed in 10% neutral-buffered formalin immediately after surgical resection and embedded in paraffin. Serial sections (3--4 μm) were mounted on adhesion slides. Immunohistochemical staining was performed with a Ventana Benchmark XT autostainer using standard autostaining protocols (Ventana Medical Systems Inc., Tucson, AZ) and all slides were processed according to the manufacturer\'s protocols. The antibodies used for biomarker expression analysis and their optimized staining conditions are described in Table [6](#T6){ref-type="table"}. Positive and negative controls were performed using the manufacturer-recommended control tissue and isotype antibody respectively.

###### Antibodies and optimizations for the immunohistochemical analysis

  Antibody   Clone                         Dilution     Source      Positive style                                                 Positive control                                Cutoff values (%)         Heat-induced antigen retrieval by 1 mM EDTA in 10 mM Tris buffer (pH 8.5)   Incubation
  ---------- ----------------------------- ------------ ----------- -------------------------------------------------------------- ----------------------------------------------- ------------------------- --------------------------------------------------------------------------- ---------------
  ERα        Rabbit monoclonal (EP1)       Prediluted   Epitomics   Nuclear staining                                               Breast cancer or human, endometrial carcinoma   ≥1                        100 °C, 30 min                                                              37 °C, 32 min
  PR         Rabbit monoclonal (EP2)       Prediluted   Epitomics   Nuclear staining                                               Breast cancer                                   ≥1                        100 °C, 30 min                                                              37 °C, 32 min
  Her-2      Rabbit monoclonal (4B5)       Prediluted   Ventana     Membrane staining                                              Breast cancer                                   According to \[[@R34]\]   100 °C, 30 min                                                              37 °C, 32 min
  CK5/6      Mouse monoclonal (D5/16 B4)   Prediluted   Dako        Membrane and/or cytoplasmic staining                           Mesothelioma                                    ≥5                        100 °C, 30 min                                                              37 °C, 32 min
  EGFR       Rabbit monoclonal (5B7)       Prediluted   Ventana     Membrane and/or cytoplasmic staining                           Skin                                            \>25                      100 °C, 30 min                                                              37 °C, 32 min
  P53        Mouse monoclonal (DO7)        Prediluted   MXB         Nuclear staining                                               Colon adenocarcinoma                            ≥5                        100 °C, 30 min                                                              37 °C, 32 min
  Ki-67      Mouse monoclonal (MIB1)       Prediluted   ZSGB-BIO    Nuclear staining                                               Breast cancer                                   ≥14                       100 °C, 30 min                                                              37 °C, 32 min
  TTK        Rabbit polyclonal             1:100        Sigma       Cytoplasmic and/ or membrane staining, rare nuclear staining   Small intestine                                 ≥55                       100 °C, 30 min                                                              37 °C, 32 min

IHC slides were evaluated by two experienced pathologists in a blinded manner. Positive staining was defined as cells with staining patterns specified in Table [6](#T6){ref-type="table"}. H-scoring was used to quantify TTK staining because no uniform standard exists \[[@R30]--[@R34]\]. For this, the overall staining intensity (0-3) was multiplied by the percentage of positive cells (0-100%), and all values were added to generate a final H-score ranging from 0 to 300. For ROC curve analysis, TTK staining was scored based on staining only in the cytoplasm and membrane ("H-score. Cytoplasm & membrane") or in the whole cell including cytoplasm, membrane and nucleus ("H-score. Whole cell"). The expression of other biomarkers was determined based on the cutoff value provided in Table [6](#T6){ref-type="table"}. For HER-2 specifically, staining intensities were rated as (0), (1+), (2+), and (3+) according to the HER2 test guide for breast cancer \[[@R35]\]. HER-2 (0) or (1+) slides were categorized as HER-2-negative, while HER-2 (3+) slides were classified as HER-2-positive. HER-2 (2+) cases were subjected to secondary analysis by fluorescent in situ hybridization (FISH) to confirm HER-2 status on a genetic basis, and those determined to be negative were enrolled in the present study. The five-biomarker immunopanel (ER, PR, HER2, CK5/6, EGFR) was also used to classify TNBC cases as basal-like (ER--/PR--/HER2-- with EGFR+ and/or CK5/6+) or non-basal-like (ER--/PR--/HER2--/EGFR--/CK5/6--).

Statistical analysis {#s4_3}
--------------------

Statistical analysis was performed in SPSS 17.0 (SPSS, Chicago, IL, USA). Qualitative variables were compared with chi-square tests and univariate log-rank testing was used to assess the associations of DFS and OS with disease covariates to identify prognostic factors. Cox regression multivariate analysis was performed to determine the significance of prognostic factors. All *p* values were two sided and considered significant at α = 0.05.

Receiver operating characteristic (ROC) curve analysis was used to assess the discriminatory power of prognostic factors to identify the optimal value of a continuous variable to differentiate between a probability of survival and death \[[@R36], [@R37]\].
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